Through our disease intelligence service, MDoutlook, Arcas has have provided insight and support for several news items since the summer:
* An article was published in the journal Value-Based Cancer Care in August 2011 about the cost implications for novel therapies in the treatment of non-small cell lung cancer (NSCLC). MDoutlook provided key insight on how the US and global community of medical oncologists will shift their management of NSCLC based on new information presented at ASCO 2011.(Article VBCC 08-2011)
* This month OBR published an article featuring immediate market insight delivered by MDoutlook to gauge the clinical impact of the recent FDA decision to revoke marketing authorization of bevacizumab (Avastin®) in HER-2 negative metastatic Breast Cancer. The article can be read here.
MDOUTLOOK, the global oncology intelligence platform, provides crucial insight into the dynamic role of clinicians involved in treating today’s oncology patient. You can read more about MDoutlook here. If you would like to talk to us or schedule a demo, please contact us at info@thearcasgroup.com.
November 23rd, 2011
We are very pleased to welcome Allison Easley to the leadership of The Arcas Group as Director, Account Services. She joins with more than 15 years of experience in servicing the pharmaceutical and biotech industry, in the United States, Europe and other regions.
Allison has used her expertise, insight and deep understanding of all Oncology/hematology tumor types in addition to respiratory medicine, immunology, critical care, and urology to design strategies and activities and meet brand objectives. She has built and utilized a variety of communication, research & media platforms for activities supporting a variety of functions at life science companies, including Commercialization Strategy, Strategic Marketing, Advocacy development, Consulting Activities, Publication Planning, Tactical Planning, Market Research, Medical Education, and Medical Communications.
“I am excited to have Allison join our team. Having worked with her in earlier stages of her career, I continue to be impressed with her high levels of energy, great insight and her dedication to consistently exceed client expectations. She is a great asset to our company and will be instrumental in expanding our relationship with our clients,” says Jan Heybroek, President of The Arcas Group.
“Arcas continues to multiply its revenue and client base through our unwavering commitment to exceed client expectations, which is highlighted by our extremely high retention client rate of 94% and the growth of business per client. Our staff rates amongst the very best in the industry, and it is a real pleasure and privilege to lead the team on the growth path we have followed from the company’s inception. This year alone we have signed on 10 new clients to our roster and have grown the MDOUTLOOK network of cancer physicians to more than 53,000 worldwide.”
November 23rd, 2011
